Chemplast Sanmar Q4 & FY26 Investor Presentation Released
Chemplast Sanmar released its Q4 & FY26 investor presentation. FY26 saw revenue of ₹4,224 crore and EBITDA of ₹198 crore. Commercial production of R32 Refrigerant Gas began in May 2026. An impairment loss of ₹898 crore was recorded on CCVL investment. A committee will explore strategic reorganization and M&A.
The investor presentation provides a comprehensive update on the company's financial and operational performance, including significant strategic initiatives like the formation of a committee to explore M&A and reorganization. The impairment loss also represents a material financial event. This information is crucial for investors to assess the company's current standing and future prospects.
The announcement is an investor presentation providing a factual update on financial performance and business operations. While it highlights some positive developments like R32 production start-up and CMCD growth, it also details significant challenges in the S-PVC segment leading to an impairment loss, balancing the overall sentiment.
Chemplast Sanmar Limited has released its Investor Presentation for the fourth quarter and full fiscal year 2026.
The presentation details performance highlights for Q4 FY'26 and FY'26, including revenues, EBITDA, and PAT. The company experienced a challenging FY'26 with consolidated revenue of ₹4,224 crore and EBITDA of ₹198 crore.
Key segment performance includes steady results in Paste PVC, with the Cuddalore facility reaching full capacity. The Custom Manufactured Chemicals Division (CMCD) saw a decent uptick in Q4 FY'26 sales, despite some deferrals, and continues to grow its product pipeline with over 45 molecules in development. Commercial production of R32 Refrigerant Gas commenced in May 2026 at the Mettur plant.
The Suspension PVC (S-PVC) business was impacted by adverse regulatory changes, leading to an impairment loss of ₹898 crore on the company's investment in CCVL, which is noted as a non-cash accounting entry. The Value-added Chemicals segment, including Caustic Soda and Hydrogen Peroxide, faced price and margin pressures due to global oversupply and weak demand.
A committee of three Independent Directors has been formed to examine strategic priorities, including potential reorganization and M&A opportunities, to enhance long-term value creation.
The company also highlighted its strong market positions in various chemical segments, its commitment to sustainability with zero liquid discharge policies, and its experienced management team and board.
What to do with a filing like this
Chemplast Sanmar Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Chemplast Sanmar Limited. Read the original for the full detail.